A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
← catalyst calendarNCT06564038 · readout in 1,027 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
408estimated
Sites
64
Countries
Australia, China, Czechia +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-30 | actual | When the study began enrolling |
| Primary completion | 2029-06-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-11 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Lymphocytic Leukaemia
- Small Lymphocytic Lymphoma
- Mantle-cell Lymphoma
- Large B-cell Lymphoma
- B-cell Non-Hodgkin Lymphoma
Interventions
- Drug: Surovatamig — also filed as AZD0486, TNB-486
- Drug: Prednisone (or equivalent)
- Drug: Rituximab
- Drug: Cyclophosphamide
- Drug: Vincristine
- Drug: Doxorubicin
- Drug: Acalabrutinib
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events, Serious Adverse Events and Adverse Events of Special Interest
measured Up to 6 years 4 months
Number of Participants with Dose Limiting Toxicity (DLTs)
measured Up to 2 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed